seminars
 
 
Contact Information

61 Biopolis Drive
Proteos
Singapore 138673
Fax: +65 6779 1117
E-mail: enquiry@imcb.a-star.edu.sg
 
Location


Click here for information on how to find IMCB

Event Videos Archive


Click here to Event Videos Archive

 
  UPCOMING EVENTS   Selected Seminar        
     
 
Date: 16 October2017
Time: 2:00pm | Level 3, IMCB Seminar Room 3-46, Proteos
Speaker: Dr. John XU
Title: Drug discovery using BsAB platform from Abpro


Abpro is a Boston based biotechnology company specialized in developing the therapeutic BsAB for treating the cancer, autoimmune and ophthalmology diseases. The company was established in 2007 by two brothers, bother are Harvard graduates. Our BsAB platform is not fixed but to be flexible based on the structures of the two antibodies we plan to link. Currently, we have two BsAB will go to clinical phase next year.  We also have a rich pipeline with more than 10 BsAB in the preclinical stage. We collaborated with several large cancer center and global pharmaceutical companies such as MedImmune and Memorial Sloan Kettering cancer center. We are looking to collaborate with many pharmaceutical companies, biotech companies and research institutes to in license or out license the good antibody projects.

Biography:
Dr. John Xu got his medical degree from Shanghai Medical University (now Fudan medical college). He has more than 13 year early drug discovery research experience in BMS and Wyeth covering oncology and CNS areas. Dr. Xu also had a very successful business development career for several large China CRO companies such as WuXi AppTec, CrownBio and HD Biosciences.  During the seven years when he was responsible for global and US business development in these CRO companies, he achieved the highest revenue for all the companies he had worked.  He had built large network in biotech and pharmaceutical companies both in the US and China. Currently, Dr. Xu serves as the Sr Vice President of strategic alliance for AbPro, a biotech company based in Boston.  His responsibility includes building the strategic partnership to develop the therapeutic bi specific antibody with global biotech and pharmaceutical companies.  Before Abpro, Dr. Xu served as the Vice president of Business development in HD Biosciences. Dr. Xu got his Master of Science and MBA degrees from US universities.

Host: Prof. Wanjin Hong

 
     

 
 
(C) Copyright 2012 Institute of Molecular and Cell Biology, A*STAR Singapore.